Related Experiment Videos
[Therapeutic effectiveness of anticoagulation in acute myocardial infarction: a case-control study]
A R Villa-Romero1, S Ponce-de-León, R Chávez-Domínguez
1Departamento de Inmunología y Reumatología, Instituto Nacional de la Nutrición Salvador Zubirán, México, D.F.
Insights
Anticoagulant therapy (AT) significantly reduces mortality in acute myocardial infarction (AMI) patients. This case-control study found AT use was associated with a 12.1-fold increased survival chance in AMI patients.
Area of Science:
- Cardiology
- Clinical Research
- Pharmacology
Context:
- Acute myocardial infarction (AMI) is a leading cause of mortality worldwide.
- Effective therapeutic strategies are crucial for improving patient outcomes.
- The role of anticoagulant therapy (AT) in AMI management requires further elucidation.
Purpose:
- To evaluate the effectiveness of anticoagulant therapy (AT) in reducing mortality among patients diagnosed with acute myocardial infarction (AMI).
Summary:
- A pair-matched case-control study analyzed 212 pairs of AMI patients (deceased vs. survived).
- Data from clinical charts at the National Institute of Cardiology, Mexico City (1975-1985) were used.
- Multiple logistic regression, controlling for antithrombotic therapy, Killip scale, and Norris index, revealed a protective odds ratio of 12.1 (p < 0.0001) for AT use.
Impact:
- Findings support a favorable therapeutic role for anticoagulant therapy in acute myocardial infarction patients.
- This research contributes to evidence-based guidelines for AMI treatment.
- Results may influence clinical practice regarding the use of AT in AMI management.
Abstract:
The main aim was to assess the role of anticoagulant therapy (AT) in reducing the mortality for patients with acute myocardial infarction (AMI). A pair-matched case-control study was designed according to three confounding factors: gender, age (+/- 5 years), and hospitalization date (+/- 13 months). Cases were defined as patients with AMI who died during hospitalization and controls were those patients with AMI who survived. Excluded from the study were patients with strong indications or contraindications for use of AT, and also those with early death (less than 12 hr). The study undertaken at the National Institute of Cardiology "Ignacio Chávez" of Mexico City and all necessary information was obtained from clinical charts of patients discharged between the period from January 1, 1975 to December 31, 1985. Complete information was accomplished for 212 pairs of cases and controls. A protective odds ratio (favoring use of AT) = 12.1 (p less than 0.0001, 95% CI 4.2-34.9) was obtained by means of a multiple logistic regression analysis by conditional method. Other variables that entered into the logistic model were: antithrombotic therapy, severity measured by Killip scale and by Norris index. Such findings support the favorable therapeutic role of AT in patients with AMI.